San Diego, CA -- (SBWIRE) -- 03/30/2017 -- Proteon Therapeutics Inc is under investigation over potential securities laws violations. The investigation was announced for investors of Proteon Therapeutics Inc (NASDAQ:PRTO) shares in connection certain financial statements made by Proteon Therapeutics Inc.

Investors who purchased shares of Proteon Therapeutics Inc (NASDAQ:PRTO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Proteon Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Waltham, MA based Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease.

On December 13, 2016, Proteon Therapeutics Inc announced that vonapanitase did not meet its primary endpoint in its first Phase 3 PATENCY-1 clinical trial. Shares of Proteon Therapeutics Inc NASDAQ:PRTO) declined from $10.58 per share on December 8, 2016 to as low as $1.51 per share on March 21, 2017.

Those who purchased shares of Proteon Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com